Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Si-Bone Inc. (SIBN:NASDAQ), powered by AI.
Si-Bone Inc. is currently trading at $15.42. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Si-Bone Inc. on Alpha Lenz.
Si-Bone Inc.'s P/E ratio is -35.0.
“Si-Bone Inc. trades at a P/E of -35.0 (undervalued) with modest ROE of -11.0%. 3Y revenue CAGR of 23.6% highlights clear growth momentum.”
Ask for details →Si-Bone Inc. is a prominent medical device company specializing in the development and commercialization of minimally invasive surgical implants for the treatment of sacroiliac joint dysfunction. Known for its iFuse Implant System, the company's primary product aims to alleviate pain and improve mobility in patients suffering from lower back issues. Si-Bone Inc. plays a crucial role in the healthcare sector, particularly within the orthopedic and spinal surgery industries. The company focuses on innovation in surgical technologies and techniques, aiming to offer safer and more effective alternatives to traditional procedures. With a strong emphasis on clinical research and education for healthcare providers, Si-Bone Inc. contributes significantly to advancing patient outcomes. Catering primarily to hospitals and surgical centers, the firm maintains a dynamic presence in both domestic and international markets. Headquartered in Santa Clara, California, Si-Bone Inc.'s innovative solutions continue to influence the evolving landscape of healthcare technology and patient care.
“Si-Bone Inc. trades at a P/E of -35.0 (undervalued) with modest ROE of -11.0%. 3Y revenue CAGR of 23.6% highlights clear growth momentum.”
Ask for details →Si-Bone Inc. (ticker: SIBN) is a company listed on NASDAQ in the Healthcare sector (Medical Devices). It has approximately 349 employees. Market cap is $662M.
The current price is $15.42 with a P/E ratio of -35.04x and P/B of 3.73x.
ROE is -10.97% and operating margin is -11.11%. Annual revenue is $201M.